Archive

HIGHLIGHTS

 
LSP Life Sciences Fund makes 250% on Ablynx sale
To read the full article click here.
 
Her Majesty Queen Máxima launches Oncode Institute, founded by LSP's Rudy Dekeyser and René Kuijten
Oncode Institute combines 600 of the very best oncology researchers with a highly qualified valorisation staff to ensure that breakthrough discoveries get to patients faster.    The origins of Oncode go back[...]
 
LSP reaches milestone: 10 years investing in listed Life Sciences Securities
LSP Life Sciences Fund generates net return of 39% in 2017   Amsterdam, January 16 2018 - LSP, the European life sciences investment group, today announced it has reached its 10 year milestone investing in li[...]
 
LSP invests in Simplify Medical to bring the company’s innovative cervical disc to the US Market
Amsterdam, the Netherlands - 12 February 2018 - LSP announces its investment in Simplify Medical. The LSP Health Economics Fund 2 (LSP HEF 2) leads the second tranche of the company’s Series B financing of $23.5 mil[...]
 
Takeda to acquire LSP portfolio company TiGenix
Takeda announces its intention to acquire TiGenix   Leuven (BELGIUM) - January 5, 2018, 7:30h CET - TiGenix NV ("TiGenix") (Euronext Brussels and NASDAQ: "TIG"), an advanced biopharmaceutical company focused [...]
 
LSP Raises EUR 280 Million to Invest In Healthcare Innovation
Largest fund in Europe dedicated to medical technology Significant fundraise reflects successful investment strategy to achieve better care at lower costs   Amsterdam, 12 December 2017 – LSP, the Europe[...]
 
Marco Groot over LSP in het FD
Amsterdam, April 11, 2017 Marco Groot over LSP in het FD Lees de gehele column: Een absoluut beter resultaat   Amsterdam, July 11, 2017: Marco Groot blikt in het FD terug op zijn eerdere positiev[...]
 
LSP leads EUR 27 mln Series A financing of new VIB start-up Aelin Therapeutics to exploit its proprietary Pept-in™ protein knockdown platform
Leuven, Belgium – 11 December 2017 – Aelin Therapeutics, a privately held Belgian biotherapeutics company, announces today that it has secured a EUR 27 million investment to pioneer a novel modality in drug develo[...]
 
De Telegraaf: gespreid in biotech en profiteren van overnames via LSP
Lees de gehele column: gespreid in biotech en profiteren van overnames via LSP
 
LSP RECOMMENDS
LSP Partner Clemens van Blitterswijk gives a TedX on the future of regenerative medicine
 
BioCentury: LSP's Four of a Kind
To read the full article click here
 
Is a cure for cancer finally within reach?
To read the full article click here
 
argenx reports positive topline results from Phase 2 proof-of-concept trial of ARGX-113 (efgartigimod) in generalized myasthenia gravis
Favorable tolerability profile consistent with Phase 1 data ARGX-113 treatment resulted in a strong clinical improvement over placebo during the entire duration of the study  75% of ARGX-113 treated p[...]

2018


Kuros Biosciences to present promising clinical case studies with MagnetOs at leading spine surgery conference
Schlieren (Zurich), Switzerland, June 19, 2018 - Kuros Biosciences will this week present results from several investigator-led clinical case studies of MagnetOs Granules at the 15thannual State of Spine Surgery Think [...]
argenx announces data from Phase 1 study of efgartigimod (ARGX-113) subcutaneous formulation demonstrating comparable characteristics to intravenous formul...
- Subcutaneous formulation offers potential for increased patient convenience and acceptance -    Breda, the Netherlands/Ghent, Belgium, June 14, 2018 - argenx (Euronext & Nasdaq: ARGX), a clinical-stage bi [...]
Zealand Pharma achieves milestone in first Phase 3 trial with dasiglucagon for the treatment of severe hypoglycemia in diabetes
Zealand Pharma achieves milestone in first Phase 3 trial with dasiglucagon for the treatment of severe hypoglycemia in diabetes   The results of the first of two completed Phase 3 trials confirm dasigluca [...]
Merus Announces First Patient Dosed in Phase 1 Clinical Trial of MCLA-158 in Patients with Solid Tumors
- IND Accepted in April by the U.S. FDA for MCLA-158 - UTRECHT, The Netherlands, May 24, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispeci [...]
eTheRNA enrols first patient in high dose cohort of Phase 1b study of TriMix mRNA-based cancer specific immunotherapy (ECI-006) in melanoma
Niel (Belgium), 24 May 2018 — eTheRNA immunotherapies, a clinical-stage company developing novel cancer immunotherapies based on its unique mRNA-based TriMix platform, announces that it has enrolled the first patien [...]
Merus Announces Unique Mechanism of Action of MCLA-128 That Potently Blocks HER3 Signaling Published in Cancer Cell
UTRECHT, The Netherlands, May 15, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced t [...]


2018
2017
2016
2015
2014
2013
2012
back to news overview
Follow us

Archive

HIGHLIGHTS

 
LSP Life Sciences Fund makes 250% on Ablynx sale
To read the full article click here.
 
Her Majesty Queen Máxima launches Oncode Institute, founded by LSP's Rudy Dekeyser and René Kuijten
Oncode Institute combines 600 of the very best oncology researchers with a highly qualified valorisation staff to ensure that breakthrough discoveries get to patients faster.    The origins of Oncode go back[...]
 
LSP reaches milestone: 10 years investing in listed Life Sciences Securities
LSP Life Sciences Fund generates net return of 39% in 2017   Amsterdam, January 16 2018 - LSP, the European life sciences investment group, today announced it has reached its 10 year milestone investing in li[...]
 
LSP invests in Simplify Medical to bring the company’s innovative cervical disc to the US Market
Amsterdam, the Netherlands - 12 February 2018 - LSP announces its investment in Simplify Medical. The LSP Health Economics Fund 2 (LSP HEF 2) leads the second tranche of the company’s Series B financing of $23.5 mil[...]
 
Takeda to acquire LSP portfolio company TiGenix
Takeda announces its intention to acquire TiGenix   Leuven (BELGIUM) - January 5, 2018, 7:30h CET - TiGenix NV ("TiGenix") (Euronext Brussels and NASDAQ: "TIG"), an advanced biopharmaceutical company focused [...]
 
LSP Raises EUR 280 Million to Invest In Healthcare Innovation
Largest fund in Europe dedicated to medical technology Significant fundraise reflects successful investment strategy to achieve better care at lower costs   Amsterdam, 12 December 2017 – LSP, the Europe[...]
 
Marco Groot over LSP in het FD
Amsterdam, April 11, 2017 Marco Groot over LSP in het FD Lees de gehele column: Een absoluut beter resultaat   Amsterdam, July 11, 2017: Marco Groot blikt in het FD terug op zijn eerdere positiev[...]
 
LSP leads EUR 27 mln Series A financing of new VIB start-up Aelin Therapeutics to exploit its proprietary Pept-in™ protein knockdown platform
Leuven, Belgium – 11 December 2017 – Aelin Therapeutics, a privately held Belgian biotherapeutics company, announces today that it has secured a EUR 27 million investment to pioneer a novel modality in drug develo[...]
 
De Telegraaf: gespreid in biotech en profiteren van overnames via LSP
Lees de gehele column: gespreid in biotech en profiteren van overnames via LSP
 
LSP RECOMMENDS
LSP Partner Clemens van Blitterswijk gives a TedX on the future of regenerative medicine
 
BioCentury: LSP's Four of a Kind
To read the full article click here
 
Is a cure for cancer finally within reach?
To read the full article click here
 
argenx reports positive topline results from Phase 2 proof-of-concept trial of ARGX-113 (efgartigimod) in generalized myasthenia gravis
Favorable tolerability profile consistent with Phase 1 data ARGX-113 treatment resulted in a strong clinical improvement over placebo during the entire duration of the study  75% of ARGX-113 treated p[...]

$smarty.now|date_format:"%Y"


Kuros Biosciences to present promising clinical case studies with MagnetOs at leading spine surgery conference
Schlieren (Zurich), Switzerland, June 19, 2018 - Kuros Biosciences will this week present results from several investigator-led clinical case studies of MagnetOs Granules at the 15thannual State of Spine Surgery Think [...]
argenx announces data from Phase 1 study of efgartigimod (ARGX-113) subcutaneous formulation demonstrating comparable characteristics to intravenous form...
- Subcutaneous formulation offers potential for increased patient convenience and acceptance -    Breda, the Netherlands/Ghent, Belgium, June 14, 2018 - argenx (Euronext & Nasdaq: ARGX), a clinical-stage bi [...]
Zealand Pharma achieves milestone in first Phase 3 trial with dasiglucagon for the treatment of severe hypoglycemia in diabetes
Zealand Pharma achieves milestone in first Phase 3 trial with dasiglucagon for the treatment of severe hypoglycemia in diabetes   The results of the first of two completed Phase 3 trials confirm dasigluca [...]
Merus Announces First Patient Dosed in Phase 1 Clinical Trial of MCLA-158 in Patients with Solid Tumors
- IND Accepted in April by the U.S. FDA for MCLA-158 - UTRECHT, The Netherlands, May 24, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispeci [...]
eTheRNA enrols first patient in high dose cohort of Phase 1b study of TriMix mRNA-based cancer specific immunotherapy (ECI-006) in melanoma
Niel (Belgium), 24 May 2018 — eTheRNA immunotherapies, a clinical-stage company developing novel cancer immunotherapies based on its unique mRNA-based TriMix platform, announces that it has enrolled the first patien [...]
Merus Announces Unique Mechanism of Action of MCLA-128 That Potently Blocks HER3 Signaling Published in Cancer Cell
UTRECHT, The Netherlands, May 15, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced t [...]


2018
2017
2016
2015
2014
2013
2012
back to news overview